[go: up one dir, main page]

PT1287001E - Derivados de tiofeno uteis como agentes anticancerigenos - Google Patents

Derivados de tiofeno uteis como agentes anticancerigenos

Info

Publication number
PT1287001E
PT1287001E PT01925786T PT01925786T PT1287001E PT 1287001 E PT1287001 E PT 1287001E PT 01925786 T PT01925786 T PT 01925786T PT 01925786 T PT01925786 T PT 01925786T PT 1287001 E PT1287001 E PT 1287001E
Authority
PT
Portugal
Prior art keywords
utious
thyrofen
anticancerigene
derivatives
agents
Prior art date
Application number
PT01925786T
Other languages
English (en)
Inventor
Michael Joseph Luzzio
Matthew Arnold Marx
Bingwei Vera Yang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PT1287001E publication Critical patent/PT1287001E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PT01925786T 2000-06-06 2001-05-02 Derivados de tiofeno uteis como agentes anticancerigenos PT1287001E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20968600P 2000-06-06 2000-06-06

Publications (1)

Publication Number Publication Date
PT1287001E true PT1287001E (pt) 2004-12-31

Family

ID=22779830

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01925786T PT1287001E (pt) 2000-06-06 2001-05-02 Derivados de tiofeno uteis como agentes anticancerigenos

Country Status (22)

Country Link
US (1) US6964961B2 (pt)
EP (1) EP1287001B1 (pt)
JP (1) JP2003535867A (pt)
AR (1) AR032621A1 (pt)
AT (1) ATE277933T1 (pt)
AU (1) AU2001252463A1 (pt)
BR (1) BR0111377A (pt)
CA (1) CA2411084A1 (pt)
DE (1) DE60106022T2 (pt)
DO (1) DOP2001000170A (pt)
EC (1) ECSP014097A (pt)
ES (1) ES2223827T3 (pt)
GT (1) GT200100104A (pt)
MX (1) MXPA02012034A (pt)
PA (1) PA8518701A1 (pt)
PE (1) PE20011373A1 (pt)
PT (1) PT1287001E (pt)
SV (1) SV2002000478A (pt)
TN (1) TNSN01082A1 (pt)
TR (1) TR200402656T4 (pt)
UY (1) UY26750A1 (pt)
WO (1) WO2001094353A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1372548A (zh) * 1999-07-01 2002-10-02 味之素株式会社 杂环化合物及其医药用途
US20030207878A1 (en) * 2000-08-09 2003-11-06 Hennequin Lawrent Francois Andre Chemical compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
CA2473468C (en) * 2002-02-01 2011-06-21 Novo Nordisk A/S Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
US7101898B2 (en) 2002-02-01 2006-09-05 Novo Nordisk A/S Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
CA2478050A1 (en) 2002-03-01 2003-09-12 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
MEP53508A (en) * 2002-06-06 2011-05-10 Boehringer Ingelheim Pharma SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
US7276519B2 (en) 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
NZ541836A (en) 2003-02-27 2008-12-24 Palau Pharma Sa Pyrazolopyridine derivatives
EP1620094A4 (en) * 2003-05-06 2010-04-28 Glaxosmithkline Llc NEW CHEMICAL COMPOUNDS
NZ545459A (en) 2003-08-14 2009-12-24 Array Biopharma Inc Quinazoline analogs as receptor tyrosine kinase inhibitors
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
WO2006010264A1 (en) 2004-07-30 2006-02-02 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
EP1957498B1 (en) 2005-05-20 2017-02-15 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
EP1904504B1 (en) 2005-05-20 2014-03-19 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
AR056200A1 (es) * 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
DE602006009968D1 (de) 2005-11-15 2009-12-03 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
US8003662B2 (en) * 2006-01-30 2011-08-23 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
JP5516397B2 (ja) 2007-04-05 2014-06-11 アムジエン・インコーポレーテツド オーロラキナーゼ調節物質及び使用方法
EP2332536A1 (en) 2008-03-05 2011-06-15 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
EP2288611B1 (en) 2008-03-20 2013-05-15 Amgen Inc. Aurora kinase modulators and method of use
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
AU2009316557B2 (en) 2008-11-19 2015-08-27 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl) benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
BRPI1014793A2 (pt) * 2009-05-11 2016-04-05 Envivo Pharmaceuticals Inc tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase
CA2799744C (en) 2010-05-17 2020-01-28 Envivo Pharmaceuticals, Inc. A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
FR3080620B1 (fr) * 2018-04-27 2021-11-12 Univ Paris Sud Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
CN113648307B (zh) * 2021-09-23 2022-09-30 河南大学 MII-tt-DTT及其在制备抗结直肠癌药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3277623D1 (en) 1981-07-31 1987-12-17 Sloan Kettering Inst Cancer Anti-leukemic beta-glycosyl c-nucleosides
WO1989008113A1 (en) 1988-03-02 1989-09-08 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-DIHYDROTHIENO[2,3-d]PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL APPLICATION THEREOF
JPH02256667A (ja) * 1988-12-27 1990-10-17 Masatoshi Yamato 縮合キノリン系化合物およびその製造方法
CA2039411A1 (en) 1990-03-30 1991-10-01 Ronnie Gerald Edie Thienopyrimidine derivatives
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
US5583137A (en) 1992-02-19 1996-12-10 Pfizer Inc. Heterocyclic compounds for enhancing antitumor activity
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
ATE247469T1 (de) 1995-06-07 2003-09-15 Pfizer Heterocyclische kondensierte pyrimidin-derivate
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
ES2200039T3 (es) 1995-12-08 2004-03-01 Pfizer Inc. Derivados heterociclicos sustituidos como antagonistas de crf.
PT882051E (pt) 1996-02-07 2002-04-29 Janssen Pharmaceutica Nv Tiofenopirimidinas
IL129825A0 (en) 1996-11-27 2000-02-29 Pfizer Fused bicyclic pyrimidine derivatives
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
BR9814018A (pt) * 1997-11-11 2000-09-26 Pfizer Prod Inc Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer

Also Published As

Publication number Publication date
US6964961B2 (en) 2005-11-15
UY26750A1 (es) 2002-01-31
ES2223827T3 (es) 2005-03-01
AR032621A1 (es) 2003-11-19
DE60106022D1 (de) 2004-11-04
PE20011373A1 (es) 2002-01-18
BR0111377A (pt) 2003-06-03
SV2002000478A (es) 2002-07-03
JP2003535867A (ja) 2003-12-02
WO2001094353A1 (en) 2001-12-13
EP1287001B1 (en) 2004-09-29
GT200100104A (es) 2002-01-31
PA8518701A1 (es) 2002-09-17
DOP2001000170A (es) 2002-05-15
TNSN01082A1 (fr) 2005-11-10
EP1287001A1 (en) 2003-03-05
MXPA02012034A (es) 2003-04-25
ATE277933T1 (de) 2004-10-15
CA2411084A1 (en) 2001-12-13
TR200402656T4 (tr) 2004-11-22
US20020042409A1 (en) 2002-04-11
ECSP014097A (es) 2003-02-06
AU2001252463A1 (en) 2001-12-17
DE60106022T2 (de) 2006-03-09

Similar Documents

Publication Publication Date Title
PT1287001E (pt) Derivados de tiofeno uteis como agentes anticancerigenos
PT1084114E (pt) Derivados isotiazole uteis como agentes anticancerigenos
AR028576A1 (es) Derivados de b-carbolina utiles como inhibidores de fosfodiesterasa
PT1177185E (pt) Derivados de 4, 5, 6, 7-tetra-hidroindazole como agentes antitumorais
AR028575A1 (es) Derivados de pirrolopiridinona utiles como inhibidores de fosfodiesterasa
DZ3439A1 (fr) Derives de 2-aminocarbonyl-9h-purine
PT1303521E (pt) Derivados de tetra-hidro-heterocicloazepinil-pirimidina
AR027967A1 (es) Derivados de esteres de pirazol como agentes antinflamatorios/analgesicos
DK1280809T3 (da) Antitumorecteinascidinderivater
ATE298332T1 (de) Decahydro-isochinolinderivate
FR2810318B1 (fr) Derives de diamano-phenothiazine
DK1368299T3 (da) Substituerede C-cyclohexylmethylaminderivater
AR028602A1 (es) Derivados de pirrol
AR028282A1 (es) Derivados de aminofenil pirimidona
ATE282021T1 (de) Substituierte aminomethyl-phenyl- cyclohexanderivate
PT1231211E (pt) Derivados de tiazolidinadiona como agentes antidiabeticos
PT1351959E (pt) Novos derivados de pleuromutilina
DK1322593T3 (da) O-substituerede-6-methyl-tramadol-derivater
PT1075471E (pt) Derivados de indolilo como agentes seronergicos
PT1246791E (pt) Derivados de aminometilfenilciclo-hexanona
PT1330453E (pt) Derivados de indolilpiperidina como agentes anti-histaminicos e antialergicos
AR028329A1 (es) Estratrienos sustituidos como estrngenos selectivamente activos
PT1073651E (pt) Derivados de indolilo como agentes serotonergicos
AR028269A1 (es) 4-hidroxicinolin-3-carboxamidas como agentes antivirales
PT1318800E (pt) 1-aminoalquilciclo-hexanos como agentes tripanocidas